Cargando…

ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis

PURPOSE: In women with postmenopausal osteoporosis, we investigated the effects of 24 months of treatment with alendronate (ALN) following 18 months of treatment with abaloparatide (ABL) or placebo (PBO). METHODS: Women who completed ABL or PBO treatment in ACTIVE were eligible to receive up to 24 m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bone, Henry G, Cosman, Felicia, Miller, Paul D, Williams, Gregory C, Hattersley, Gary, Hu, Ming-yi, Fitzpatrick, Lorraine A, Mitlak, Bruce, Papapoulos, Socrates, Rizzoli, René, Dore, Robin K, Bilezikian, John P, Saag, Kenneth G
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Endocrine Society 2018
Materias:	Clinical Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6097601/ https://www.ncbi.nlm.nih.gov/pubmed/29800372 http://dx.doi.org/10.1210/jc.2018-00163

Ejemplares similares

Abaloparatide followed by alendronate in women ≥80 years with osteoporosis: post hoc analysis of ACTIVExtend
por: Greenspan, Susan L., et al.
Publicado: (2020)

Effect of Abaloparatide vs Alendronate on Fracture Risk Reduction in Postmenopausal Women With Osteoporosis
por: Leder, Benjamin Z, et al.
Publicado: (2019)

Response rates for hip, femoral neck, and lumbar spine bone mineral density in patients treated with abaloparatide followed by alendronate: Results from phase 3 ACTIVExtend
por: Deal, Chad L., et al.
Publicado: (2019)

Fracture and Bone Mineral Density Response by Baseline Risk in Patients Treated With Abaloparatide Followed by Alendronate: Results From the Phase 3 ACTIVExtend Trial
por: Leder, Benjamin Z, et al.
Publicado: (2019)

Forearm bone mineral density and fracture incidence in postmenopausal women with osteoporosis: results from the ACTIVExtend phase 3 trial
por: Watts, N.B., et al.
Publicado: (2020)

Cardiovascular Safety of Abaloparatide in Postmenopausal Women With Osteoporosis: Analysis From the ACTIVE Phase 3 Trial
por: Cosman, Felicia, et al.
Publicado: (2020)

OR03-1 The Effect of Abaloparatide on Bone Mineral Density and Fracture Incidence in Postmenopausal Women with Osteoporosis and Osteoarthritis
por: Lane, Nancy, et al.
Publicado: (2019)

Abaloparatide in Postmenopausal Women With Osteoporosis and Type 2 Diabetes: A Post Hoc Analysis of the ACTIVE Study
por: Dhaliwal, Ruban, et al.
Publicado: (2020)

Geography of Fracture Incidence in Postmenopausal Women with Osteoporosis Treated with Abaloparatide
por: McClung, Michael R., et al.
Publicado: (2017)

Erratum for Abaloparatide in Postmenopausal Women With Osteoporosis and Type 2 Diabetes: A Post Hoc Analysis of the ACTIVE Study
por: Dhaliwal, Ruban, et al.
Publicado: (2020)

Correction to: Geography of Fracture Incidence in Postmenopausal Women with Osteoporosis Treated with Abaloparatide
por: McClung, Michael R., et al.
Publicado: (2018)

Abaloparatide effect on forearm bone mineral density and wrist fracture risk in postmenopausal women with osteoporosis
por: Watts, N.B., et al.
Publicado: (2019)

Correction to: Abaloparatide effect on forearm bone mineral density and wrist fracture risk in postmenopausal women with osteoporosis
por: Watts, N. B., et al.
Publicado: (2020)

Correction to: Abaloparatide effect on forearm bone mineral density and wrist fracture risk in postmenopausal women with osteoporosis
por: Watts, N. B., et al.
Publicado: (2020)

ERRATUM for “Effect of Abaloparatide vs Alendronate on Fracture Risk Reduction in Postmenopausal Women With Osteoporosis”
Publicado: (2020)

Abaloparatide is an Effective Treatment Option for Postmenopausal Osteoporosis: Review of the Number Needed to Treat Compared with Teriparatide
por: Reginster, Jean-Yves, et al.
Publicado: (2018)

Cost-effectiveness Analysis of Sequential Treatment of Abaloparatide Followed by Alendronate Versus Teriparatide Followed by Alendronate in Postmenopausal Women With Osteoporosis in the United States
por: Le, Quang A., et al.
Publicado: (2018)

Early Effects of Abaloparatide on Bone Formation and Resorption Indices in Postmenopausal Women With Osteoporosis
por: Dempster, David W, et al.
Publicado: (2021)

Comparative effectiveness and cardiovascular safety of abaloparatide and teriparatide in postmenopausal women new to anabolic therapy: A US administrative claims database study
por: Cosman, F., et al.
Publicado: (2022)

Profile of Abaloparatide and Its Potential in the Treatment of Postmenopausal Osteoporosis
por: Tella, Sri Harsha, et al.
Publicado: (2017)

The Efficacy and Safety of Abaloparatide‐SC in Men With Osteoporosis: A Randomized Clinical Trial
por: Czerwinski, Edward, et al.
Publicado: (2022)

Phase 1b Evaluation of Abaloparatide Solid Microstructured Transdermal System (Abaloparatide-sMTS) in Postmenopausal Women with Low Bone Mineral Density
por: Miller, Paul D., et al.
Publicado: (2021)

Abaloparatide for risk reduction of nonvertebral and vertebral fractures in postmenopausal women with osteoporosis: a network meta-analysis
por: Reginster, J. -Y., et al.
Publicado: (2019)

Modulating Bone Resorption and Bone Formation in Opposite Directions in the Treatment of Postmenopausal Osteoporosis
por: Appelman-Dijkstra, Natasha M., et al.
Publicado: (2015)

Alendronate improves QOL of postmenopausal women with osteoporosis
por: Kawate, Hisaya, et al.
Publicado: (2010)

Proximal Femur Responses to Sequential Therapy With Abaloparatide Followed by Alendronate in Postmenopausal Women With Osteoporosis by 3D Modeling of Hip Dual‐Energy X‐Ray Absorptiometry (DXA)
por: Winzenrieth, Renaud, et al.
Publicado: (2022)

Once-monthly risedronate for postmenopausal osteoporosis
por: Casadei, Kristina, et al.
Publicado: (2010)

Combination and sequential treatments in the management of osteoporosis
por: Papapoulos, Socrates
Publicado: (2012)

Seven years’ experience with alendronate in postmenopausal Japanese women with osteoporosis
por: Iwamoto, Jun, et al.
Publicado: (2010)

Cost-Effectiveness of Sequential Abaloparatide/Alendronate in Men at High Risk of Fractures in the United States
por: Hiligsmann, Mickaël, et al.
Publicado: (2023)

SAT-519 Effect of Abaloparatide on Bone Mineral Density and Fracture Incidence in a Subset of Younger Postmenopausal Women with Osteoporosis at High Risk for Fracture Representative of Covered Commercial Insurance Enrollees
por: Saag, Kenneth, et al.
Publicado: (2019)

Abaloparatide-SC improves trabecular microarchitecture as assessed by trabecular bone score (TBS): a 24-week randomized clinical trial
por: Bilezikian, J. P., et al.
Publicado: (2017)

Bone turnover markers to explain changes in lumbar spine BMD with abaloparatide and teriparatide: results from ACTIVE
por: Eastell, R., et al.
Publicado: (2019)

Knowledge and compliance towards alendronate therapy among postmenopausal women with osteoporosis in Palestine
por: Radwan, Asma, et al.
Publicado: (2022)

Is abaloparatide more efficacious on increasing bone mineral density than teriparatide for women with postmenopausal osteoporosis? An updated meta-analysis
por: Hong, Pan, et al.
Publicado: (2023)

Sclerostin Inhibition in the Management of Osteoporosis
por: Appelman-Dijkstra, Natasha M., et al.
Publicado: (2016)

Effects of abaloparatide and teriparatide on bone resorption and bone formation in female mice()
por: Arlt, Heike, et al.
Publicado: (2020)

OR03-2 Different Effects of Abaloparatide and h-PTH(1-34) on Osteoclastogenesis and Bone Resorption
por: Arlt, Heike, et al.
Publicado: (2019)

Hip fracture protection by alendronate treatment in postmenopausal women with osteoporosis: a review of the literature
por: Iwamoto, Jun, et al.
Publicado: (2008)

Cost-effectiveness of teriparatide compared with alendronate and risedronate for the treatment of postmenopausal osteoporosis patients in Iran
por: Ebadi Fard Azar, Amir Ali, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_d883cmi7qc9ofu8isqc3ku6i69